Holen Sie sich die Stockscreener-App
13.21
0.68%
-0.09
Handel nachbörslich:
13.21
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 3.6%Should You Buy? - MarketBeat
The Manufacturers Life Insurance Company Cuts Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
(PLRX) Trading Signals - Stock Traders Daily
Pliant Therapeutics (STU:9PT) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.57 Average Target Price from Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Great Point Partners LLC Has $21.41 Million Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics (STU:9PT) Change In Inventory : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily
Atria Investments Inc Takes Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
PLRX (Pliant Therapeutics) Market Cap : $789.88 Mil (As of Nov. 24, 2024) - GuruFocus.com
PLRX (Pliant Therapeutics) Earnings Yield % : N/A% (As of Nov. 24, 2024) - GuruFocus.com
Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan
Vietnamese Dong/Canadian Dollar (VNDCAD) QuotePress Release - The Globe and Mail
Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire
Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan
Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com
First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com
Objective long/short (PLRX) Report - Stock Traders Daily
Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK
Fresh Del Monte Produce (FDP-N) QuotePress Release - The Globe and Mail
Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK
HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat
SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News
Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle
An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily
The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
How To Trade (PLRX) - Stock Traders Daily
Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat
Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com
Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):